Grit Bio Inc, spun out of the Mount Sinai School of Medicine, researches and develops cancer therapeutics and peptide technologies that target the metabolism of cancer. The company's primary technology is a peptide inhibitor of the metabolic enzyme Acid Ceramidase and has the potential to be used in combination with chemo and radiation therapies or consecutively.
